- Company
- Next-Generation ADC Enhertu launches in Korea
- by jung, sae-im Jan 16, 2023 07:39pm
- Enhertu, which Korean breast cancer patients urged for quick permission last year, was released in Korea this month. Analysts say that it will change the paradigm of secondary treatment for HER2-positive breast cancer with a superior effect compared to existing treatments. Daiichi Sankyo held a press conference at the Westin Chosun Hotel on the
- Company
- Last year's drug trade deficit was the largest ever
- by Kim, Jin-Gu Jan 16, 2023 06:03am
- Vaccine exports hit an all-time high, but have been on the decline since the second half of the year. Last year, pharmaceutical exports fell 23% year-on-year. The export performance of medicines, which had been on a high march for two years from 2020 to 2021, is gradually returning to the previous year's level as the global spread of COVID-19 su
- Company
- GM Lee Seung-woo to leave Gilead Sciences Korea
- by Eo, Yun-Ho Jan 16, 2023 06:02am
- Paul Seung-woo Lee (65), who has served as the General Manager of Gilead Sciences Korea and led the company since its establishment, will be leaving the company. According to industry sources, Lee has recently expressed his intent to resign upon the expiry of his term to the company. Accordingly, Gilead is currently in the process of hiri
- Company
- Bosulif approved in Korea 11 years after US approval
- by Jan 16, 2023 06:02am
- The Ministry of Food and Drug Safety approved the new drug for chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), ‘Bosulif (bosutinib)’ in Korea. The drug was first approved in the US in 2012. With the approval, the treatment options for Ph+CML increased to 6, excluding the first-generation drug. Accor
- Company
- RET-targeted Retevmo lands in general hospitals in KOR
- by Eo, Yun-Ho Jan 13, 2023 06:02am
- The RET-targeted anticancer therapy ‘Retevmo’ may now be prescribed at general hospitals in Korea. According to industry sources, Lilly Korea’s, Lilly Korea’s Retevmo (selpercatinib) passed the drug committees of tertiary hospitals in Korea including the Samsung Medical Center, Seoul National University Hospital, and Seoul St. Mary’s H
- Company
- GC Pharma exclusively distributes and sells Baraclude
- by Kim, Jin-Gu Jan 13, 2023 06:01am
- GC Pharma announced on the 11th that it will extend the contract to sell Baraclude, a hepatitis B treatment by BMS Korea, and expand its partnership to exclusive distribution and sales. The two companies have continued their partnership related to Baraclude since September 2015. Through this contract, GC Pharma strengthened its influence
- Company
- Baxter's core business unit spun off
- by jung, sae-im Jan 12, 2023 04:32am
- Baxter will spin off its key business unit. The industry expects the division to become independent and sell it to private equity funds. In the aftermath, the Korean branch is reducing its workforce. According to the pharmaceutical industry on the 12th, Baxter Korea recently conducted voluntary retirement (ERP) for its employees. Those who ha
- Company
- Celltrion launches Stella PO development with U.S. Rani
- by Jan 12, 2023 04:30am
- Celltrion announced on the 9th that it has signed a contract with Rani Theraputics, a bio company in San Jose, USA, to develop Stella PO. Celltrion exclusively supplies Rani Theraputics with the Stella biosimilar CT-P43, which is needed for Stella PO (RT-111) non-clinical and phase 1 clinical trials. In the future, it will have priority ne
- Company
- 80 companies participated in the K-Cab patent dispute
- by Kim, Jin-Gu Jan 12, 2023 04:30am
- The patent dispute over HK Innoen's gastroesophageal reflux disease treatment K-Cab has expanded to the largest scale ever. A total of 80 companies challenged HK inno.N. According to the pharmaceutical industry on the 10th, a total of 80 companies have challenged K-Cab crystalline patents by the 9th. On December 24 last year, SCD filed a pass
- Company
- Dupixent to be reviewed by DREC for reimb after 2 years
- by Eo, Yun-Ho Jan 12, 2023 04:29am
- The atopic dermatitis treatment ‘Dupixent’ has taken a step forward in extending reimbursement to children and adolescents. According to industry sources, the low-dose formulation (200mg) of Sanofi-Aventis Korea’s Dupixent (dupilumab) will be deliberated by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evalua
